Cargando…
High Throughput Screening in Duchenne Muscular Dystrophy: From Drug Discovery to Functional Genomics
Centers for the screening of biologically active compounds and genomic libraries are becoming common in the academic setting and have enabled researchers devoted to developing strategies for the treatment of diseases or interested in studying a biological phenomenon to have unprecedented access to l...
Autores principales: | Gintjee, Thomas J.J., Magh, Alvin S.H., Bertoni, Carmen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4280510/ https://www.ncbi.nlm.nih.gov/pubmed/25405319 http://dx.doi.org/10.3390/biology3040752 |
Ejemplares similares
-
Clinical potential of ataluren in the treatment of Duchenne muscular dystrophy
por: Namgoong, John Hyun, et al.
Publicado: (2016) -
Drug Discovery for Duchenne Muscular Dystrophy via Utrophin Promoter Activation Screening
por: Moorwood, Catherine, et al.
Publicado: (2011) -
Emerging gene editing strategies for Duchenne muscular dystrophy targeting stem cells
por: Bertoni, Carmen
Publicado: (2014) -
Newborn screening for Duchenne muscular dystrophy‐early detection and diagnostic algorithm for female carriers of Duchenne muscular dystrophy
por: Gruber, Dorota, et al.
Publicado: (2022) -
Drug development progress in duchenne muscular dystrophy
por: Deng, Jiexin, et al.
Publicado: (2022)